Endometrial cancer, also known as uterine cancer, begins in the uterus and is commonly found early due to its unsettling symptoms. Even though its cause is unknown, a genetic mutation is thought to assist in its onset. Risk for developing endometrial cancer increases with changes in hormones, obesity, increasing age, earlier onset of menstruation, having hereditary nonpolyposis colorectal cancer, and various hormone therapies. Treatments for endometrial cancer include surgery, radiation, hormone therapy, and chemotherapy. Recurrent endometrial cancer is defined when the cancer returns after it has been previously treated. The cancer may be localized in the uterus or may have spread to the pelvis, lymph nodes, abdomen, or other various distant locations throughout the body.
Recurrent Endometrial Cancer Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Recurrent Endometrial Cancer below!
For more information on how to use Laverne, please read the How to Guide.
We have 2126 products for the study of Recurrent Endometrial Cancer that can be applied to Chromatin Immunoprecipitation, Flow Cytometry, Western Blot, Immunocytochemistry/Immunofluorescence, Immunohistochemistry, Chromatin Immunoprecipitation (ChIP) from our catalog of antibodies and ELISA kits.
Recurrent Endometrial Cancer is also known as Endometrial Cancer Recurrent, Endometrial Carcinoma Recurrent, Recurrent Carcinoma Of The Endometrium, Recurrent Uterine Cancer, Recurrent Uterine Corpus Cancer.